1. Induction Pegylated Interferon Alfa-2b in Combination With Ribavirin in Patients With Genotypes 1 and 4 Chronic Hepatitis C: A Prospective, Randomized, Multicenter, Open- Label Study 
Daniel E. Brady, Dawn M. Torres, Jong W. An, John A. Ward, Eric Lawitz, Stephen A. Harrison 
Clinical Gastroenterology and Hepatology 
Volume 8, Issue 1, Pages e1 (January 2010)
DOI: /j.cgh
Copyright © 2010 AGA Institute Terms and Conditions

2. Figure 1
Study schematic outlining randomization to specific study arm, dose and duration of study medication, and follow-up time interval.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

3. Figure 2
Percentage of virus negativity seen at weeks 12, 24, 48, and 72 for each study group.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

4. Figure 3
Weight subgroup analysis. Percentage of virus negativity at weeks 12, 24, 48, and 72 for each study group separated by weight.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions

5. Supplementary Figure 1
Consolidated Standards of Reporting Trials (CONSORT) patient flow diagram.
Clinical Gastroenterology and Hepatology 2010 8, e1DOI: ( /j.cgh )
Copyright © 2010 AGA Institute Terms and Conditions